MK-886 - A NOVEL MECHANISM, ORALLY ACTIVE LEUKOTRIENE BIOSYNTHESIS INHIBITOR

被引：0

作者：

GILLARD, JW

MORTON, HE

DIXON, R

EVANS, J

FORTIN, R

GAUTHIER, JY

MACFARLANE, C

MILLER, D

ROUZER, C

VICKERS, P

FORDHUTCHINSON, AW

机构：

[1] MERCK FROSST CTR THERAPEUT RES,POINTE CLAIRE H9R 4PB,QUEBEC,CANADA

[2] MERCK & CO INC,RAHWAY,NJ 07065

来源：

ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 1990年 / 199卷

关键词：

D O I：

暂无

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

引用

页码：150 / MEDI

共 50 条

[41] STRUCTURE-ACTIVITY ANALYSIS OF A CLASS OF ORALLY ACTIVE HYDROXAMIC ACID INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS
SUMMERS, JB
GUNN, BP
MARTIN, JG
MARTIN, MB
MAZDIYASNI, H
STEWART, AO
YOUNG, PR
BOUSKA, JB
GOETZE, AM
DYER, RD
BROOKS, DW
CARTER, GW
JOURNAL OF MEDICINAL CHEMISTRY, 1988, 31 (10) : 1960 - 1964
[42] Five-lipoxygenase-activating protein inhibitor MK-886 induces apoptosis in gastric cancer through upregulation of p27kip1 and bax
Fan, XM
Tu, SP
Lam, SK
Wang, WP
Wu, J
Wong, WM
Yuen, MF
Lin, MCM
Kung, HF
Wong, BCY
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2004, 19 (01) : 31 - 37
[43] MK-5204: An orally active β-1,3-glucan synthesis inhibitor
Apgar, James M.
Wilkening, Robert R.
Parker, Dann L., Jr.
Meng, Dongfang
Wildonger, Kenneth J.
Sperbeck, Donald
Greenlee, Mark L.
Balkovec, James M.
Flattery, Amy M.
Abruzzo, George K.
Galgoci, Andrew M.
Giacobbe, Robert A.
Gill, Charles J.
Hsu, Ming-Jo
Liberator, Paul
Misura, Andrew S.
Motyl, Mary
Kahn, Jennifer Nielsen
Powles, Maryann
Racine, Fred
Dragovic, Jasminka
Fan, Weiming
Kirwan, Robin
Lee, Shu
Liu, Hao
Mamai, Ahmed
Nelson, Kingsley
Peel, Michael
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2020, 30 (17)
[44] INHIBITION OF LEUKOTRIENE-B4 BIOSYNTHESIS BY A NOVEL PHOSPHODIESTERASE INHIBITOR
KRUPKA, U
PELSTER, B
PROSTAGLANDINS, 1984, 28 (05): : 639 - 639
[45] MK-8353: Discovery of an Orally Bioavailable Dual Mechanism ERK Inhibitor for Oncology
Boga, Sobhana Babu
Deng, Yongqi
Zhu, Liang
Nan, Yang
Cooper, Alan B.
Shipps, Gerald W., Jr.
Doll, Ronald
Shih, Neng-Yang
Zhu, Hugh
Sun, Robert
Wang, Tong
Paliwal, Sunil
Tsui, Hon-Chung
Gao, Xiaolei
Yao, Xin
Desai, Jagdish
Wang, James
Alhassan, Abdul Basit
Kelly, Joseph
Patel, Mehul
Muppalla, Kiran
Gudipati, Subrahmanyam
Zhang, Li-Kang
Buevich, Alexei
Hesk, David
Carr, Donna
Dayananth, Priya
Black, Stuart
Mei, Hong
Cox, Kathleen
Sherborne, Bradley
Hruza, Alan W.
Xiao, Li
Jin, Weihong
Long, Brian
Liu, Gongjie
Taylor, Stacey A.
Kirschmeier, Paul
Windsor, William T.
Bishop, Robert
Samatar, Ahmed A.
ACS MEDICINAL CHEMISTRY LETTERS, 2018, 9 (07): : 761 - 767
[46] An automated sample preparation and high performance liquid chromatographic method for the determination of MK-591, a novel leukotriene biosynthesis inhibitor, in human plasma
Lin, C
Hsieh, JYK
Matuszewski, BK
Dobrinska, MR
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1996, 14 (11) : 1601 - 1608
[47] Pharmacological characterization of a novel orally active neutrophil elastase inhibitor
Kuromiya, A
Okazaki, H
Tsuji, J
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 230 : U2691 - U2692
[48] Pharmacology of a Novel, Orally Active PDE4 Inhibitor
Dastidar, Sunanda G.
Ray, Abhijit
Shirumalla, Rajkumar
Rajagopal, Deepa
Chaudhary, Shiwani
Nanda, Kamna
Sharma, Pawan
Seth, Mahesh Kumar
Balachandran, Sarala
Gupta, Nidhi
Palle, Venkata
PHARMACOLOGY, 2009, 83 (05) : 275 - 286
[49] A Novel, Nonpeptidic, Orally Active Bivalent Inhibitor of Human β-Tryptase
Giardina, Sarah F.
Werner, Douglas S.
Pingle, Maneesh
Bergstrom, Donald E.
Arnold, Lee D.
Barany, Francis
PHARMACOLOGY, 2018, 102 (5-6) : 233 - 243
[50] Orally active αvβ3 integrin inhibitor MK-0429 reduces melanoma metastasis
Pickarski, Maureen
Gleason, Alexa
Bednar, Bohumil
Duong, Let.
ONCOLOGY REPORTS, 2015, 33 (06) : 2737 - 2745

← 1 2 3 4 5 →